Computational Design and Biopharmaceutical Evaluation of a Chimeric Nanoparticle Vaccine for Targeted Delivery against BK Polyomavirus
Pharmaceutical Research · 2026
DOI: 10.1007/s11095-026-04100-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, 2026. Verfasst von Amin Zahmatkesh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: BK Virus, Nanoparticles, Polyomavirus Infections, Viral Vaccines. Die Arbeit nennt 86 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To address the unmet need for a prophylactic therapy against BK polyomavirus (BKPV) in transplant recipients, this study employed a mechanism-based computational approach to design a multi-epitope chimeric nanoparticle (CNP) vaccine, predicting its biopharmaceutical and immunological profile. METHODS: A comprehensive computational biopharmaceutics pipeline was implemented. Conserved and immunodominant B-cell, helper T-lymphocyte (HTL), and cytotoxic T-lymphocyte (CTL) epitopes from all major BKPV proteins were identified using immunoinformatic tools. Epitopes were rigorously validated for antigenicity, safety, global population coverage, and cross-reactivity potential against JC polyomavirus. A multi-epitope construct, fused with immune-potentiating peptides, was designed and displayed on an Encapsulin nanocage via the SpyTag/SpyCatcher system to create a targeted delivery platform. RESULTS: Molecular docking and dynamics simulations demonstrated stable, high-affinity binding of the vaccine construct and the CNP with Toll-like receptors 2 and 4, predicting effective innate immune recognition. In silico immune simulation forecasted robust and durable humoral and cellular immune responses upon administration. CONCLUSIONS: This integrated computational study provides a mechanistic rationale for a novel CNP vaccine candidate against BKPV. The predicted stability, immunogenicity, and targeted delivery potential establish a strong foundation for subsequent in vitro and in vivo development, aligning with the translation of computational design into biopharmaceutical products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
- NoushDaru Intelligent Pars Company, Biotechnology Incubator, Shiraz University of Medical Sciences, Shiraz, Iran.
- Department of Bacteriology & Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. hoseiniy@sums.ac.ir.
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland. hoseiniy@sums.ac.ir.
- Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. rayaviro@yahoo.com.
Zitieren
APA
Zahmatkesh, A., Faraji, S. N., Hosseini, S. Y., & Yaghobi, R. (2026). Computational Design and Biopharmaceutical Evaluation of a Chimeric Nanoparticle Vaccine for Targeted Delivery against BK Polyomavirus. Pharmaceutical Research. https://doi.org/10.1007/s11095-026-04100-9
Vancouver
Zahmatkesh A, Faraji SN, Hosseini SY, Yaghobi R. Computational Design and Biopharmaceutical Evaluation of a Chimeric Nanoparticle Vaccine for Targeted Delivery against BK Polyomavirus. Pharmaceutical Research. 2026. doi:10.1007/s11095-026-04100-9
BibTeX
@article{Zahmatkesh2026,
author = {Zahmatkesh, Amin and Faraji, Seyed Nooreddin and Hosseini, Seyed Younes and Yaghobi, Ramin},
title = {Computational Design and Biopharmaceutical Evaluation of a Chimeric Nanoparticle Vaccine for Targeted Delivery against BK Polyomavirus},
journal = {Pharmaceutical Research},
year = {2026},
doi = {10.1007/s11095-026-04100-9}
}
EUVIMED